PD-L1 expression as predictor of immunotherapy eligibility in penile squamous cell carcinoma patients.xlsx

PD-L1 is a tumor marker that co-stimulates the receptor PD-1 to suppress T-cell-mediated antitumor immunity. Seventy-six biopsy sample were taken from patients diagnosed with penile squamous cell carcinoma who have already undergone penile biopsy. PD-LI expression was assessed on cytoplasm and/or tumor cell membranes and TILs. PD-LI staining was performed on 500 tumor cells and 100 TILs. Semi-quantitative assessment refers to research by Chovanec <em>et al.</em> who used histoscore (H-score). The percentage of stained cells was assessed on a scale of 0-100%. Intensity measurement then given a score of 0-3 (0= none; 1= weak; 2= moderate; and 3= strong).<br> <br>